Cargando…

Use of Antimuscarinics in the Elderly

Overactive bladder (OAB) is a common, costly, and treatable condition in older persons. There is a wide array of available antimuscarinics for the treatment of these conditions; however, their side effect profile and the limited number of studies that evaluate their effect in the elderly curb their...

Descripción completa

Detalles Bibliográficos
Autores principales:	Patel, Bhavin, Bavendam, Tamara, Badlani, Gopal
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	TheScientificWorldJOURNAL 2009
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5823097/ https://www.ncbi.nlm.nih.gov/pubmed/19526185 http://dx.doi.org/10.1100/tsw.2009.55

Ejemplares similares

Bladder antimuscarinics and cognitive decline in elderly patients
por: Moga, Daniela Claudia, et al.
Publicado: (2017)

An Overview of the Clinical Use of Antimuscarinics in the Treatment of Overactive Bladder
por: Athanasopoulos, Anastasios, et al.
Publicado: (2011)

High satisfaction with direct switching from antimuscarinics to mirabegron in patients receiving stable antimuscarinic treatment
por: Liao, Chun-Hou, et al.
Publicado: (2016)

Maintenance of the Therapeutic Effect of Two High-Dosage Antimuscarinics in the Management of Overactive Bladder in Elderly Women
por: Kosilov, Kirill, et al.
Publicado: (2013)

Comparative study of different combinations of mirabegron and antimuscarinics in treatment for overactive bladder syndrome in elderly patients
por: Kuo, Yuh-Chen, et al.
Publicado: (2021)

Choice of antimuscarinic agents for overactive bladder in the older patient: focus on darifenacin
por: Chughtai, Bilal, et al.
Publicado: (2008)

Treatment of pediatric antimuscarinic delirium with oral rivastigmine
por: Yakey, Brandtly, et al.
Publicado: (2023)

Pharmacist‐driven interventions to de‐escalate urinary antimuscarinics in the Programs of All‐Inclusive Care for the Elderly
por: Ha, Meghan, et al.
Publicado: (2022)

The use of antimuscarinics, phosphodiesterase type V inhibitors and phytotherapy for lower urinary tract symptoms in men
por: Ng, Kok Kit, et al.
Publicado: (2017)

Novel research approaches for interstitial cystitis/bladder pain syndrome: thinking beyond the bladder
por: Mullins, Chris, et al.
Publicado: (2015)

Characterization of Bladder Selectivity of Antimuscarinic Agents on the Basis of In Vivo Drug-Receptor Binding
por: Yamada, Shizuo, et al.
Publicado: (2012)

International volunteerism and global responsibility
por: Badlani, Gopal
Publicado: (2017)

Comparison of antimuscarinic drugs to beta adrenergic agonists in overactive bladder: A literary review
por: Wani, Mudassir M., et al.
Publicado: (2021)

In vivo antimuscarinic actions of the third generation antihistaminergic agent, desloratadine
por: Howell, G, et al.
Publicado: (2005)

Patterns of use of antimuscarinic drugs to treat overactive bladder in Denmark, Sweden, and the United Kingdom
por: Margulis, Andrea V., et al.
Publicado: (2018)

Mirabegron and antimuscarinic use in frail overactive bladder patients in the United States Medicare population
por: Johnson, Theodore M., et al.
Publicado: (2022)

Economic Impact of Mirabegron Versus Antimuscarinics for the Treatment of Overactive Bladder in the UK
por: Nazir, Jameel, et al.
Publicado: (2017)

Critical appraisal of the Spanner™ prostatic stent in the treatment of prostatic obstruction
por: McKenzie, Patrick, et al.
Publicado: (2011)

Antimuscarinics for neurogenic overactive bladder in multiple sclerosis: real-life data
por: Andretta, Elena, et al.
Publicado: (2022)

Patterns of Potentially Inappropriate Bladder Antimuscarinic Use in People with Dementia: A Retrospective Cohort Study
por: Green, Ariel R., et al.
Publicado: (2020)

A meta-analysis of the placebo response in antimuscarinic drug trials for overactive bladder
por: Lee, Soyon, et al.
Publicado: (2009)

The Science behind Biomaterials in Female Stress Urinary Incontinence Surgery
por: Amrute, Kaytan V., et al.
Publicado: (2009)

Mesh complications in female pelvic floor reconstructive surgery and their management: A systematic review
por: Shah, Hemendra N., et al.
Publicado: (2012)

Treatment of Severe Swallowing Dysfunction in Systemic Sclerosis with IVIG: Role of Antimuscarinic Antibodies
por: Mendoza, Fabian A., et al.
Publicado: (2022)

Dr. Atul Thakre
por: Badlani, Gopal
Publicado: (2009)

When it takes a pandemic to help us forget our conflicts
por: Badlani, Gopal
Publicado: (2020)

An investigation of factors predicting the type of bladder antimuscarinics initiated in Medicare nursing homes residents
por: Moga, Daniela C., et al.
Publicado: (2017)

Risk of delirium associated with antimuscarinics in older adults: A case‐time‐control study
por: Nishtala, Prasad S., et al.
Publicado: (2022)

Cost Effectiveness of Mirabegron Compared with Antimuscarinic Agents for the Treatment of Adults with Overactive Bladder in Colombia
por: Parise, Hélène, et al.
Publicado: (2019)

Use of bladder antimuscarinics is associated with an increased risk of dementia: a retrospective population-based case–control study
por: Harnod, Tomor, et al.
Publicado: (2021)

Exposure to antimuscarinic medications for treatment of overactive bladder and risk of lung cancer and colon cancer
por: Löfling, Lukas, et al.
Publicado: (2019)

Update on Lower Urinary Tract Symptoms
por: Badlani, Gopal H.
Publicado: (2009)

Recent updates in the management of urinary incontinence
por: Badlani, Gopal H.
Publicado: (2007)

Differential pharmacological and sex-specific effects of antimuscarinic agents at the hypoglossal motor nucleus in vivo in rats
por: Niakani, Sepehr, et al.
Publicado: (2022)

Adverse Event Assessment of Antimuscarinics for Treating Overactive Bladder: A Network Meta-Analytic Approach
por: Kessler, Thomas M., et al.
Publicado: (2011)

Antimuscarinic Agent Treatment Affecting Patient-Reported Outcomes in Overactive Bladder Syndrome With Depressive Symptoms
por: Kim, Kyu Shik, et al.
Publicado: (2016)

Long-Term Efficacy of Mirabegron Add-On Therapy to Antimuscarinic Agents in Patients With Spinal Cord Injury
por: Han, Seok-Hee, et al.
Publicado: (2019)

Cost-effectiveness of solifenacin compared with oral antimuscarinic agents for the treatment of patients with overactive bladder in the UK
por: Hakimi, Zalmai, et al.
Publicado: (2018)

Persistence with mirabegron or antimuscarinic treatment for overactive bladder syndrome: Findings from the PERSPECTIVE registry study
por: Carlson, Kevin V., et al.
Publicado: (2021)

A new tool for self-evaluation of adherence to antimuscarinic drugs treatment in patients with urinary incontinence
por: Kosilov, Kirill V., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_hu7nmoqvcn4h35uth8c9k9pto8